Background

The Falsified Medicines Directive prescribes mandatory, harmonised safety features on all human prescription medicines packs (with certain risk-based exceptions) marketed in the EU. These safety features shall consist of a unique identifier combined with an anti-tampering device for each pack. The information about the safety features will be stored in a database and each pack must be verified in connection with dispensing to the customer/patient. The goal is to prevent falsified medicines from reaching patients through the legal supply chain.

Read more

Pharmaceutical companies (MAHs)

Many preparations are needed in order for companies and other stakeholders to meet the requirements of the directive in February 2019. A large number of packs, systems and procedures are involved. It is therefore crucial to plan and prepare implementation as much as possible.

Read more

Pharmacies/Wholesalers

The requirements apply beginning on Feb. 9, 2019 when marking of packaging and IT systems for verification must be fully implemented. All paticipants in the supply chain of medicines are concerned . This places great demands on all participants in the supply chain,

Read more

SMVS

SMVS is the Swedish national system for the verification and decommisioning of products in scope of the Delegated Regulation 2016/161. The SMVS is part of the European Medicines Verifications System (EMVS). Follow changes in the status.

Read more

Q&A

Deployment of a new pharmaceutical services system requires changes in many different systems and methods. Below are answers to some of the questions that e-VIS and the implementation project have received, including a large amount of relevant documents.

Read more